Search Results - "Brasó‐Maristany, Fara"

Frequency and spectrum of PIK3CA somatic mutations in breast cancer by Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, Prat, Aleix

“…The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced…”
Get full text

Biomarkers of immunotherapy response in breast cancer beyond PD-L1 by Chic, Nuria, Brasó-Maristany, Fara, Prat, Aleix

“…Immune checkpoint inhibitors have modified the treatment algorithm in a variety of cancer types, including breast cancer. Nevertheless, optimal selection of…”
Get full text

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade by Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix

“…The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20–60% of HER2+/HER2-E tumors…”
Get full text

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes by Schettini, Francesco, Brasó-Maristany, Fara, Kuderer, Nicole M., Prat, Aleix

Get full text

Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer by Dieci, Maria Vittoria, Conte, PierFranco, Bisagni, Giancarlo, Bartolini, Stefania, Frassoldati, Antonio, Generali, Daniele, Piacentini, Federico, Griguolo, Gaia, Tagliafico, Enrico, Brasó Maristany, Fara, Chic, Nuria, Paré, Laia, Miglietta, Federica, Vicini, Roberto, D’Amico, Roberto, Balduzzi, Sara, Prat, Aleix, Guarneri, Valentina

“…Abstract Background Even with contemporary treatment strategies, more than 10% of HER2-positive early stage breast cancer patients may experience distant…”
Get full text

Gene expression profiles of breast cancer metastasis according to organ site by Brasó‐Maristany, Fara, Paré, Laia, Chic, Nuria, Martínez‐Sáez, Olga, Pascual, Tomás, Mallafré‐Larrosa, Meritxell, Schettini, Francesco, González‐Farré, Blanca, Sanfeliu, Esther, Martínez, Débora, Galván, Patricia, Barnadas, Esther, Salinas, Belinda, Tolosa, Pablo, Ciruelos, Eva, Carcelero, Esther, Guillén, Cecilia, Adamo, Barbara, Moreno, Reinaldo, Vidal, Maria, Muñoz, Montserrat, Prat, Aleix

“…In advanced breast cancer, biomarker identification and patient selection using a metastatic tumor biopsy is becoming more necessary. However, the biology of…”
Get full text

CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition by Andreu-Saumell, Irene, Rodriguez-Garcia, Alba, Mühlgrabner, Vanessa, Gimenez-Alejandre, Marta, Marzal, Berta, Castellsagué, Joan, Brasó-Maristany, Fara, Calderon, Hugo, Angelats, Laura, Colell, Salut, Nuding, Mara, Soria-Castellano, Marta, Barbao, Paula, Prat, Aleix, Urbano-Ispizua, Alvaro, Huppa, Johannes B., Guedan, Sonia

“…Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces significant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The…”
Get full text

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer by Patel, Nirmesh, Weekes, Daniel, Drosopoulos, Konstantinos, Gazinska, Patrycja, Noel, Elodie, Rashid, Mamun, Mirza, Hasan, Quist, Jelmar, Brasó-Maristany, Fara, Mathew, Sumi, Ferro, Riccardo, Pereira, Ana Mendes, Prince, Cynthia, Noor, Farzana, Francesch-Domenech, Erika, Marlow, Rebecca, de Rinaldis, Emanuele, Grigoriadis, Anita, Linardopoulos, Spiros, Marra, Pierfrancesco, Tutt, Andrew N. J.

“…Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate frequent copy number aberrations (CNAs). Here, we describe an…”
Get full text

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer by Lorman-Carbó, Natàlia, Martínez-Sáez, Olga, Fernandez-Martinez, Aranzazu, Galván, Patricia, Chic, Nuria, Garcia-Fructuoso, Isabel, Rodríguez, Adela, Gómez-Bravo, Raquel, Schettini, Francesco, Blasco, Paula, Castillo, Oleguer, González-Farré, Blanca, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Perou, Charles M., Malumbres, Marcos, Gavilá, Joaquín, Pascual, Tomás, Prat, Aleix, Brasó-Maristany, Fara

“…This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase…”
Get full text

Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer by Díaz-Gil, Laura, Brasó-Maristany, Fara, Locatelli, Claudriana, Centa, Ariana, Győrffy, Balász, Ocaña, Alberto, Prat, Aleix, Pandiella, Atanasio

“…Trastuzumab-based therapies are the therapeutic option for HER2 positive (HER2+) breast cancer. HER2 amplification is the only biomarker validated for…”
Get full text

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report by Schettini, Francesco, Seguí, Elia, Conte, Benedetta, Sanfeliu, Esther, Gonzalez-Farre, Blanca, Jares, Pedro, Vidal-Sicart, Sergi, Ganau, Sergi, Cebrecos, Isaac, Brasó-Maristany, Fara, Muñoz, Montserrat, Prat, Aleix, Vidal, Maria

“…CDK4/6 inhibitors (CDKi), namely, palbociclib, ribociclib, and abemaciclib, combined with either an aromatase inhibitor (AI) or fulvestrant are the standard…”
Get full text

Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease by Isola, Ignacio, Brasó-Maristany, Fara, Moreno, David F, Mena, Mari-Pau, Oliver-Calders, Aina, Paré, Laia, Rodríguez-Lobato, Luis Gerardo, Martin-Antonio, Beatriz, Cibeira, María Teresa, Bladé, Joan, Rosiñol, Laura, Prat, Aleix, Lozano, Ester, Fernández de Larrea, Carlos

“…We previously reported algorithms based on clinical parameters and plasma cell characteristics to identify patients with smoldering multiple myeloma (SMM) with…”
Get full text

Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease by Isola, Ignacio, Moreno, David F., Moga, Esther, Mena, Mari-Pau, Tovar, Natalia, Rodríguez-Lobato, Luis Gerardo, Oliver-Caldés, Aina, Salgado, M. Carmen, Brasó-Maristany, Fara, Yagüe, Jordi, Cibeira, M. Teresa, Prat, Aleix, Rosiñol, Laura, Bladé, Joan, Fernández de Larrea, Carlos

“…Smoldering multiple myeloma (SMM) is an asymptomatic and biologically heterogeneous plasma cell disorder, with a highly variable clinical course…”
Get full text

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer by Brasó-Maristany, Fara, Sansó, Miriam, Chic, Nuria, Martínez, Débora, González-Farré, Blanca, Sanfeliu, Esther, Ghiglione, Lucio, Carcelero, Esther, Garcia-Corbacho, Javier, Sánchez, Marcelo, Soy, Dolors, Jares, Pedro, Peg, Vicente, Saura, Cristina, Muñoz, Montserrat, Prat, Aleix, Vivancos, Ana

“…The immune checkpoint inhibitor atezolizumab is approved for PD-L1-positive triple-negative breast cancer (TNBC). However, no activity of atezolizumab in…”
Get full text

Reply to Bertucci, De Nonneville, and Finetti by Brasó-Maristany, Fara, Prat, Aleix

Get full text

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy by Chic, Nuria, Schettini, Francesco, Brasó-Maristany, Fara, Sanfeliu, Esther, Adamo, Barbara, Vidal, Maria, Martínez, Débora, Galván, Patricia, González-Farré, Blanca, Cortés, Javier, Gavilá, Joaquín, Saura, Cristina, Oliveira, Mafalda, Pernas, Sònia, Martínez-Sáez, Olga, Soberino, Jesús, Ciruelos, Eva, Carey, Lisa A., Muñoz, Montserrat, Perou, Charles M., Pascual, Tomás, Bellet, Meritxell, Prat, Aleix

“…Chemotherapy efficacy in early-stage hormone receptor-positive (HR+) breast cancer (BC) according to menopausal status needs a biological explanation. We…”
Get full text

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy by Pascual, Tomás, Fernandez-Martinez, Aranzazu, Agrawal, Yash, Pfefferle, Adam D., Chic, Nuria, Brasó-Maristany, Fara, Gonzàlez-Farré, Blanca, Paré, Laia, Villacampa, Guillermo, Saura, Cristina, Hernando, Cristina, Muñoz, Montserrat, Galván, Patricia, Gonzàlez-Farré, Xavier, Oliveira, Mafalda, Gil-Gil, Miguel, Ciruelos, Eva, Villagrasa, Patricia, Gavilá, Joaquín, Prat, Aleix, Perou, Charles M.

“…In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the…”
Get full text

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy by Martínez-Sáez, Olga, Pascual, Tomás, Brasó-Maristany, Fara, Chic, Nuria, González-Farré, Blanca, Sanfeliu, Esther, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Anna Belén, Schettini, Francesco, Conte, Benedetta, Vidal, Maria, Adamo, Barbara, Martínez, Antoni, Muñoz, Montserrat, Moreno, Reinaldo, Villagrasa, Patricia, Salvador, Fernando, Ciruelos, Eva M., Faull, Iris, Odegaard, Justin I., Prat, Aleix

“…Circulating tumor DNA (ctDNA) levels may predict response to anticancer drugs, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET);…”
Get full text

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies by Prat, Aleix, Chaudhury, Anwesha, Solovieff, Nadia, Paré, Laia, Martinez, Débora, Chic, Nuria, Martínez-Sáez, Olga, Brasó-Maristany, Fara, Lteif, Agnes, Taran, Tetiana, Babbar, Naveen, Su, Fei

“…The prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast…”
Get full text

Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer by Falato, Claudette, Schettini, Francesco, Pascual, Tomás, Brasó-Maristany, Fara, Prat, Aleix

“…•All the IS can be identified within HoR+/HER2–negative disease.•Luminal IS evolve toward a more aggressive non-luminal IS.•IS are prognostic in early-stage…”
Get full text